Sanofi-Aventis Zimulti (clarification)
Executive Summary
FDA data analysis presented at a recent advisory committee on rimonabant for weight loss suggests the product has a greater suicidality risk than competitors; it did not specifically address class risk for suicidality (1"The Pink Sheet" June 25, 2007, p. 23). Some of the data presented at the advisory committee session also was drawn from animal studies...
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.